OXB

As OXB expands its US presence, we remain focused on strengthening how we serve our clients and accelerating the delivery of life-changing therapies to patients worldwide. Our new Durham site brings: 🔹 17,500 sq. ft. of operational production area to support advancing programmes with significant expansion potential 🔹 GMP manufacturing and fill-finish capabilities, supported by state-of-the-art MSAT and QC labs 🔹 FDA-approved facilities ready for late-stage and commercial programmes 🔹 A strengthened US presence offering greater flexibility and regional support This expansion builds on OXB’s commitment to flexibility, quality, and partnership, reinforcing our ability to support our clients’ therapies from early development through commercial delivery. #CellAndGeneTherapy #AdvancedTherapies #ViralVectors #CDMO #OXB

𝗢𝘂𝗿 #ESGCT2025 𝗽𝗼𝘀𝘁𝗲𝗿𝘀 𝗮𝗿𝗲 𝗻𝗼𝘄 𝗹𝗶𝘃𝗲 𝗼𝗻 𝗼𝘂𝗿 𝘄𝗲𝗯𝘀𝗶𝘁𝗲! Thank you to our scientists Alissa Bray, Oliver Goodyear and Laura Devlin, who represented OXB and shared our latest innovations in Seville last week.   🔗 Explore all ESGCT posters here: https://lnkd.in/ec6E3NDq #AdvancedTherapies #CellAndGeneTherapy #ViralVectors #CDMO #OXB

We’re proud to be named a winner in the 𝗖𝗲𝗹𝗹 & 𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 category at the 𝟮𝟬𝟮𝟱 𝗖𝗗𝗠𝗢 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗔𝘄𝗮𝗿𝗱𝘀 𝗘𝘂𝗿𝗼𝗽𝗲! 🏆 This award, based on client feedback across Europe, reflects the trust our clients place in us and the dedication of our teams who work every day to support the development and delivery of life-changing therapies to patients. With over 30 years of experience in viral vector development and manufacturing, we’re committed to delivering flexible, reliable solutions that move therapies efficiently from development to commercial scale. Thank you to our clients and our team, together we’re driving the progress that helps bring these therapies to patients faster. #CDMOLeadershipAwardsEurope #OXBWins #CellAndGeneTherapy #AdvancedTherapies #ViralVectors #CDMO #OXB 

OXB is live at #ESGCT2025 in Seville this week!   Visit 𝗕𝗼𝗼𝘁𝗵 𝗔𝟭𝟰 to meet our team and explore how OXB’s tailored CDMO solutions can help move your cell and gene therapy programme forward.   If you’re in Seville, come say hello!   #MeetOXB #CellAndGeneTherapy #AdvancedTherapies #ViralVectors #CDMO #OXB

We are delighted to announce that we are expanding our US footprint with the acquisition of a commercial-scale viral vector facility in North Carolina.     This acquisition strengthens our global CDMO network, adding scalable vector manufacturing capabilities and end-to-end services across drug substance and fill-finish. It will support late-stage programmes and commercial launches, helping to meet growing demand from new and existing clients.   Read the full press release here: https://lnkd.in/e6GCcKuJ    #OXB #CDMO #CellAndGeneTherapy #Acquisition

Did you know? OXB-manufactured vectors are already supporting therapies in 𝟰𝟬+ 𝗰𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀 worldwide 🌍   Behind every approval is the expertise of our team, years of innovation, and close collaboration with our partners, all with one goal: getting life-changing therapies to patients.   🔗 Explore our Knowledge Centre for case studies and insights into how OXB supports therapies worldwide: https://lnkd.in/e-BatrDP #FunFactFriday #CellAndGeneTherapy #AdvancedTherapies #ViralVectors #CDMO #OXB

Only one week to go until #ESGCT2025! We’re proud to sponsor this year’s meeting in Seville, 7–10 October. Alongside our scientific poster presentations, our team will be at 𝗕𝗼𝗼𝘁𝗵 𝗔𝟭𝟰, ready to discuss how OXB’s flexible CDMO solutions can help accelerate your therapy from development through to clinical and commercial delivery. Meet our Business Development team attending: 🔹 Sandrine Lopes, Head of Business Development 🔹 Edouard Weill, Director of Business Development 🔹 Loriane Dhaussy, Director of Business Development 📩 If you’re attending, now’s the perfect time to book a meeting. Reach out directly to our team or email us at [email protected] to arrange a time in Seville. #CellAndGeneTherapy #AdvancedTherapies #ViralVectors #CDMO #OXB

𝗦𝗲𝗮𝗺𝗹𝗲𝘀𝘀 𝘁𝗲𝗰𝗵 𝘁𝗿𝗮𝗻𝘀𝗳𝗲𝗿 𝗮𝗰𝗿𝗼𝘀𝘀 𝗯𝗼𝗿𝗱𝗲𝗿𝘀 – 𝗡𝗲𝘄 𝗰𝗮𝘀𝗲 𝘀𝘁𝘂𝗱𝘆  We know that successful tech transfer is more than just moving processes, it’s about maintaining quality, speed, and confidence.  In our latest case study, we share how we seamlessly transferred our proprietary LentiVector™ platform from the UK to a newly acquired site in France. Using our structured yet agile five-stage tech transfer model, we delivered:  🔹 A fully comparable lentiviral process   🔹 100% of analytical methods within acceptance criteria   🔹 On-time, on-budget execution This project reinforces OXB’s position as a global CDMO partner capable of scaling complex platforms internationally. 📥 Download the full case study to explore our approach: https://bit.ly/4n6H7JX #TechnologyTransfer #CellandGeneTherapy #AdvancedTherapies #ViralVectors #CDMO #OXB

𝗢𝗫𝗕 𝗶𝘀 𝗵𝗲𝗮𝗱𝗲𝗱 𝘁𝗼 𝗣𝗵𝗼𝗲𝗻𝗶𝘅 𝗳𝗼𝗿 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗲𝘀𝗮, 𝟲–𝟴 𝗢𝗰𝘁𝗼𝗯𝗲𝗿!  We’re proud to be a sponsor of this year’s event, where our Chief Business Officer, Sébastien Ribault, Head of Business Development, Sharmilee Patel, and Director of Business Development, Shyamali Mandal, MSc., Ph.D., will be there to connect, share insights, and explore how we can support your project.    📩 If you’re attending, you can reach out to Sharmilee and Shyamali directly or email us at [email protected] to book a meeting.   #CGMesa25 #CellAndGeneTherapy #AdvancedTherapies #ViralVectors #CDMO #OXB

This morning, we published our interim results which demonstrate strong execution, continued operational and commercial momentum, as well as a clear pathway to profitability. Highlights include: 🔹 Total revenues increased 44% to £73.2 million 🔹 Contracted value of client orders rose 166% to £149 million improving long-term revenue visibility 🔹 Improved operational efficiency alongside high demand for late-stage and commercial programme activity 🔹 Strong half-year performance reinforces confidence in near- and medium-term outlook Read the full statement here: https://lnkd.in/eSmehnpY The OXB management team, led by our Chief Executive Officer, Dr. Frank Mathias; Chief Financial Officer, Dr Lucinda (Lucy) Crabtree, PhD; and Chief Business Officer, Dr Sébastien Ribault, will be hosting a virtual analyst briefing and Q&A session today at 1:00 PM BST / 8:00 AM ET. #OXB #CDMO #CellAndGeneTherapy #ViralVectors #InterimResults